ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Stock Information for Ikena Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ikena Oncology Inc.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - ALBT, NDOI, DNB, RSLS
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - ALBT, NDOI, DNB, RSLS
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.